Almirall, S.A. announced that the Board of Directors have approved the appointment of Mr. Gianfranco Nazzi as CEO of the Board of Directors effective May 1, 2021. Mr. Nazzi joins Almirall from Teva Pharmaceuticals Industries Ltd, where he has most recently been serving as Executive Vice President of the International Markets Region and as a member of the Teva Executive Committee. While at Teva over the past seven years, he has held roles of increasing responsibility and geographic scope based in Israel and the Netherlands. He held the position of Senior Vice President Specialty Medicines Europe and President and CEO Growth Markets Region. Mr. Nazzi will take over the CEO duties from Mike McClellan, who at the beginning of the year was appointed interim CEO in addition to his role as CFO after the company's former Chief Executive Officer, Peter Guenter, left Almirall on December 31st to pursue other professional endeavors.
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.